Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 11/20 | 0.49 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.46 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MYC | P01106 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1156930 | 0.81 | GABRA1 (0.50) | MAPTTSHRLMNAKDM4E | |
| SCHEMBL9400147 | 0.80 | NR4A2 (0.49) | NR4A2CREBBPMAP2K1MAPTTSHR | |
| SCHEMBL4046793 | 0.78 | NR4A2 (0.47) | NR4A2CREBBPMAP2K1 | |
| SCHEMBL7689425 | 0.78 | BRPF1 (0.42) | NR4A2KDM4E | |
| SCHEMBL28944544 | 0.78 | NOTUM (0.50) | MYCKDM4EGLAGAA | |
| SCHEMBL1156174 | 0.77 | NR4A2 (0.45) | NR4A2CREBBPMAP2K1MAPTTSHR | |
| SCHEMBL1156225 | 0.77 | NR4A2 (0.45) | NR4A2CREBBPMAP2K1TSHRLMNA | |
| SCHEMBL6022280 | 0.76 | NR4A2 (0.45) | NR4A2CREBBPMAP2K1LMNA | |
| SCHEMBL1155973 | 0.74 | NR4A2 (0.43) | NR4A2CREBBPMAP2K1MAPTTSHR | |
| SCHEMBL69740 | 0.74 | NR4A2 (0.48) | NR4A2CREBBPMAP2K1MAPTMYC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114456098-B | Preparation method of medicine Ai Shali ketone for treating diabetic nephropathy | 大连理工大学 | 2024-06-14 | — | — | CN | claimed |
| CN-114456098-A | Preparation method of diabetic nephropathy medicine namely elsamiloride | 大连理工大学 | 2022-05-10 | — | — | CN | claimed |
| CN-114456098-B | Preparation method of medicine Ai Shali ketone for treating diabetic nephropathy | 大连理工大学 | 2024-06-14 | — | — | CN | disclosed |
| CN-114456098-A | Preparation method of diabetic nephropathy medicine namely elsamiloride | 大连理工大学 | 2022-05-10 | — | — | CN | disclosed |
| US-10308605-B2 | Proton pump inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-04 | — | — | US | disclosed |
| EP-2336107-B1 | Proton pump inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2015-09-23 | — | — | EP | disclosed |
| EP-2349997-B1 | ATROPISOMERS OF (HYDROXYALKYL) PYRROLE DERIVATIVES | EXELIXIS INC (US) | 2015-08-12 | — | — | EP | disclosed |
| US-20140343070-A1 | PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-20 | — | — | US | disclosed |
| EP-2327692-B9 | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-)aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2014-06-04 | — | — | EP | disclosed |
| US-8487117-B2 | Atropisomers of (hydroxyalkyl) pyrrole derivatives | EXELIXIS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8436187-B2 | 1-heterocyclylsulfonyl, 3-aminomethyl, 5- (hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| WO-2010042622-A1 | ATROPISOMERS OF (HYDROXYALKYL) PYRROLE DERIVATIVES | EXELIXIS, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| US-20090275591-A1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2009-11-05 | — | — | US | disclosed |
| US-20090143444-A1 | ACID SECRETION INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-04 | — | — | US | disclosed |
| US-7498337-B2 | Acid secretion inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-03 | — | — | US | disclosed |
| US-20080139639-A1 | 3-amino(alkyl)-substituted pyrrole compounds such as N-methyl-1-[1-(phenylsulfonyl)-5-(3-thienyl)-1H-pyrrol-3-yl]methanamine; peptic ulcer, Zollinger-Ellison syndrome, gastritis, gastroesophageal reflux disease, gastric cancer, ulcer caused by non-steroidal anti-inflammatory agent (NSAID) use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-06-12 | — | — | US | disclosed |
| EP-1919865-A1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2008-05-14 | — | — | EP | disclosed |
| EP-1803709-A1 | PROTON PUMP INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2007-07-04 | — | — | EP | disclosed |
| US-20070060623-A1 | antiulcer agents; proton pump inhibitors; side effect reduction; 1-[4-fluoro-5-phenyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine; superior acid secretion inhibitory effect; peptic ulcer, Zollinger-Ellison syndrome, reflux esophagitis, or symptomatic gastroesophageal reflux disease | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-15 | — | — | US | disclosed |
| WO-2007026916-A1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143444-A1 | ACID SECRETION INHIBITOR | HRH2, VIP, CCKBR | NR4A2 1760/4885CREBBP 3195/4885MAP2K1 2755/4885 |
| US-20140343070-A1 | PROTON PUMP INHIBITORS | HRH2, HRH4, CYP2C19 | NR4A2 1498/4885CREBBP 2399/4885MAP2K1 1465/4885 |
| US-10308605-B2 | Proton pump inhibitors | HRH2, HRH4, HRH1 | NR4A2 1507/4885CREBBP 2233/4885MAP2K1 1709/4885 |
| US-20080139639-A1 | 3-amino(alkyl)-substituted pyrrole compounds such as N-methyl-1-[1-(phenylsulfonyl)-5-(3-thienyl)-1H-pyrrol-3-yl]methanamine; peptic ulcer, Zollinger-Ellison syndrome, gastritis, gastroesophageal reflux disease, gastric cancer, ulcer caused by non-steroidal anti-inflammatory agent (NSAID) use | PTGER1, PTGER3, NR3C1 | NR4A2 554/4885CREBBP 1375/4885MAP2K1 2320/4885 |
| US-20090275591-A1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITOR | HRH2, ASNS, GHSR | NR4A2 2373/4885CREBBP 3146/4885MAP2K1 1626/4885 |
| US-20070060623-A1 | antiulcer agents; proton pump inhibitors; side effect reduction; 1-[4-fluoro-5-phenyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine; superior acid secretion inhibitory effect; peptic ulcer, Zollinger-Ellison syndrome, reflux esophagitis, or symptomatic gastroesophageal reflux disease | HRH2, GIPR, HRH4 | NR4A2 943/4885CREBBP 1236/4885MAP2K1 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.